Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
27. Februar 2023 16:30 ET
|
Neuronetics
MALVERN, Pa., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics Expands NeuroStar® Advanced Therapy’s Proprietary TrakStar® Platform
23. Februar 2023 08:56 ET
|
Neuronetics
MALVERN, Pa., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics to Report Fourth Quarter 2022 Financial and Operating Results and Host Conference Call
22. Februar 2023 16:35 ET
|
Neuronetics
MALVERN, Pa., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics Sponsors the 5th International Brain Stimulation Conference
21. Februar 2023 08:53 ET
|
Neuronetics
MALVERN, Pa., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics Announces Elevation of Sara Grubbs to SVP, Chief Revenue Officer
16. Februar 2023 16:12 ET
|
Neuronetics
MALVERN, Pa., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics Announces Updated Medicare Policy Expanding Access to NeuroStar TMS Therapy through Nurse Practitioners
10. Februar 2023 16:15 ET
|
Neuronetics
MALVERN, Pa., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics and Greenbrook TMS Announce Six Year Exclusive Partnership
19. Januar 2023 08:30 ET
|
Neuronetics
MALVERN, Pa. and TORONTO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing, and marketing products...
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
18. Januar 2023 16:29 ET
|
Neuronetics
MALVERN, Pa., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics Announces Data Confirming Efficacy in Treating Anxious Depression with NeuroStar® Advanced Therapy for Mental Health
17. Januar 2023 08:32 ET
|
Neuronetics
MALVERN, Pa., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics Settles Litigation Against BrainsWay
10. Januar 2023 08:00 ET
|
Neuronetics
MALVERN, Pa., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...